Skip to main
ZBH
ZBH logo

ZBH Stock Forecast & Price Target

ZBH Analyst Ratings

Based on 36 analyst ratings
Buy
Strong Buy 17%
Buy 33%
Hold 42%
Sell 6%
Strong Sell 3%

Bulls say

Zimmer Biomet Holdings is projected to achieve sales of $7.85 billion and adjusted EPS of $8.23 by 2025, reflecting year-over-year growth of 4.0% and 2.9% respectively, aligning with current guidance expectations. The company's recent sales in the surgical equipment and technology (SET) segment of $489 million surpassed consensus estimates and demonstrated notable growth, indicating positive momentum in higher-growth end-markets. Furthermore, the anticipated operational margin expansion linked to the spin-off of ZimVie is expected to contribute significantly to overall performance, with management highlighting increased market penetration and traction from new product launches in the underserved knee and hip segments.

Bears say

The analysis indicates a negative outlook on Zimmer Biomet Holdings due to anticipated revenue growth slowing to 2% or less, primarily driven by weaker sales from the ROSA robot and disappointing new product launches, alongside ongoing margin contraction that could lead to below-consensus earnings. Additionally, the company faces several risks, including potential challenges in the orthopedic market, pricing pressures on implant sales, and possible dilutive effects from its Paragon acquisition and foreign exchange headwinds. Finally, the projected adjusted EPS guidance of $8.25 at the midpoint, which is below the consensus estimate of $8.56, further underscores the company's financial challenges and diminished growth expectations.

ZBH has been analyzed by 36 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 33% recommend Buy, 42% suggest Holding, 6% advise Selling, and 3% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zimmer Biomet Hlds and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zimmer Biomet Hlds (ZBH) Forecast

Analysts have given ZBH a Buy based on their latest research and market trends.

According to 36 analysts, ZBH has a Buy consensus rating as of Jul 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $125.81, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $125.81, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zimmer Biomet Hlds (ZBH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.